Lu Zhang
China Pharmaceutical University(CN)
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Biochemical and Molecular Research, Glycosylation and Glycoproteins Research, Ubiquitin and proteasome pathways
Most-Cited Works
- → Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation(2020)363 cited
- → Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target(2019)252 cited
- → Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol(2020)166 cited
- → Intra-host variation and evolutionary dynamics of SARS-CoV-2 populations in COVID-19 patients(2021)143 cited
- → Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma(2019)138 cited
- → Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation(2022)116 cited
- → Design, synthesis, and preliminary biological evaluation of novel ethyl 1-(2′-hydroxy-3′-aroxypropyl)-3-aryl-1H-pyrazole-5-carboxylate(2006)114 cited
- → Bone Marrow Vascular Niche: Home for Hematopoietic Stem Cells(2014)84 cited
- → Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma(2022)83 cited
- → Multi-platform omics analysis reveals molecular signature for COVID-19 pathogenesis, prognosis and drug target discovery(2021)79 cited